Free Trial

Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals logo
$39.69 -0.24 (-0.60%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$40.15 +0.46 (+1.17%)
As of 07/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TARS vs. LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, CRSP, ADMA, and PCVX

Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Tarsus Pharmaceuticals vs. Its Competitors

Legend Biotech (NASDAQ:LEGN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Legend Biotech has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

In the previous week, Legend Biotech had 9 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 11 mentions for Legend Biotech and 2 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.13 beat Legend Biotech's score of 0.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tarsus Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Legend Biotech currently has a consensus price target of $72.60, indicating a potential upside of 93.65%. Tarsus Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 67.97%. Given Legend Biotech's higher possible upside, research analysts clearly believe Legend Biotech is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91
Tarsus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Legend Biotech has a net margin of -29.95% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Legend Biotech's return on equity of -21.19% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-29.95% -21.19% -13.47%
Tarsus Pharmaceuticals -44.91%-39.72%-25.74%

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$627.24M10.98-$177.03M-$0.59-63.54
Tarsus Pharmaceuticals$182.95M9.11-$115.55M-$2.73-14.54

Summary

Legend Biotech beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARS vs. The Competition

MetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.68B$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-14.5420.8027.0020.10
Price / Sales9.11286.27428.95120.24
Price / CashN/A41.1936.8257.86
Price / Book6.767.487.985.56
Net Income-$115.55M-$55.04M$3.16B$248.40M
7 Day Performance-1.88%2.44%2.39%4.67%
1 Month Performance-7.93%1.90%2.18%6.64%
1 Year Performance40.30%4.35%33.82%21.31%

Tarsus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARS
Tarsus Pharmaceuticals
1.8604 of 5 stars
$39.69
-0.6%
$66.67
+68.0%
+40.3%$1.68B$182.95M-14.5450Positive News
LEGN
Legend Biotech
3.0571 of 5 stars
$35.87
+0.6%
$72.60
+102.4%
-20.9%$6.55B$627.24M-60.802,609Analyst Forecast
GRFS
Grifols
4.088 of 5 stars
$8.87
-2.3%
$10.30
+16.1%
+7.0%$6.24B$7.81B7.5823,822Analyst Upgrade
TGTX
TG Therapeutics
3.8984 of 5 stars
$35.98
-2.0%
$40.80
+13.4%
+82.1%$5.83B$329M149.92290Positive News
NUVL
Nuvalent
3.7498 of 5 stars
$77.93
-3.2%
$119.60
+53.5%
+8.9%$5.78BN/A-17.7540
LNTH
Lantheus
4.4181 of 5 stars
$79.19
-1.5%
$130.50
+64.8%
+4.6%$5.56B$1.53B22.50700
TLX
Telix Pharmaceuticals
N/A$15.48
-3.7%
$22.33
+44.3%
N/A$5.44B$516.72M0.00N/A
AXSM
Axsome Therapeutics
4.7367 of 5 stars
$107.50
+2.0%
$172.33
+60.3%
+29.6%$5.19B$385.69M-18.63380
CRSP
CRISPR Therapeutics
2.9811 of 5 stars
$51.19
-1.9%
$71.75
+40.2%
+3.0%$4.51B$37.31M-11.33460Analyst Forecast
ADMA
ADMA Biologics
4.1301 of 5 stars
$17.88
-2.2%
$27.67
+54.7%
+53.0%$4.36B$426.45M21.04530Positive News
PCVX
Vaxcyte
1.5822 of 5 stars
$32.00
-3.8%
$136.50
+326.6%
-57.8%$4.29BN/A-8.02160

Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners